<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030248</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00028749</org_study_id>
    <nct_id>NCT03030248</nct_id>
  </id_info>
  <brief_title>Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population</brief_title>
  <official_title>Randomized Double Blind Controlled Trial for the Treatment of Nucleic Acid Amplification Test (NAAT)+/Toxin Enzyme Immunoassay (EIA)- Clostridium Difficile in the Hematology Oncology Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Jackson Laboratory for Genomic Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is good evidence that randomizing C. difficile NAAT(+), toxin(-) patients to
      non-treatment represents an ethically tolerable risk-benefit, even in cancer patients and
      hematopoetic stem cell transplant (HSCT) recipients. Actually, detection of free toxin in the
      stool was the standard of care for the diagnosis of C. difficile infection (CDI) from 1983
      through 2010. Since then, NAAT became the standard diagnostic test for over 60% of US
      hospitals (National Healthcare Safety Network, unpublished data). However, there is growing
      evidence that symptomatic patients who are NAAT(+), toxin(-) have outcomes similar to
      patients who are NAAT(-), toxin(-); some of these outcomes include 30-day mortality, ICU
      admission, and hospital readmission triggered by C. difficile. Furthermore, the United
      Kingdom has successfully used a similar two step diagnostic algorithm with a confirmatory
      toxin EIA since 2012.

      The adverse health consequences resulting from antibiotic overtreatment of NAAT(+), toxin(-)
      patients may be particularly important in transplant recipients. The usual treatment
      prescribed for CDI at the Froedtert Memorial Lutheran Hospital is oral vancomycin. While this
      drug has excellent activity against C. difficile and commonly suppresses its growth to
      non-detection, it does not eradicate carriage and its use results in marked and prolonged
      disruption of the lower intestinal microbiota. Meanwhile, the degree of lower intestinal
      microbiota disruption at the time of HSCT engraftment has been demonstrated to be an
      independent predictor (controlling for other markers of underlying disease) of overall and
      transplant-related 3-year mortality.14 In addition, recent findings suggest that bone marrow
      suppressive effects of antibiotics, in this case potentially unnecessary oral vancomycin
      (which is not appreciably absorbed), may be solely mediated via microbiota disruption. All
      these data supports the notion that antibiotic treatment of NAAT(+), toxin(-) C. difficile
      patients might have significant negative repercussions without a clear clinical benefit.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be divided into two groups, one receiving oral vancomycin capsules, the other receiving oral placebo capsules.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The allocation status of patients within this study will be held in sealed envelopes by the research pharmacist on the team. Neither the main care provider, study physicians, or the patient will know of their group, until either the end of the study (after data analysis).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Clostridium difficile bacterial loads in the stool</measure>
    <time_frame>Pre-treatment, 1, 7, 14, 21, 28, and 90 days past the beginning of treatment</time_frame>
    <description>Changes in Clostridium difficile bacterial counts from stool as determined by quantitative polymerase chain reaction (PCR)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Vancomycin treated group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be given placebo oral capsules every 6 hours for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Oral Capsule</intervention_name>
    <description>We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.</description>
    <arm_group_label>Vancomycin treated group</arm_group_label>
    <other_name>Vancocin hydrochloride Oral Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD&amp;C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the hematology oncology inpatient units at Froedtert Memorial
             Lutheran Hospital

          -  Having had a bone marrow transplantation (stem cell transplant) within the past 24
             months

          -  Positive C. difficile surveillance test (NAAT) upon unit admission

          -  New onset of diarrhea during hospitalization

          -  C. difficile clinical testing showing NAAT positive EIA negative results

        Exclusion Criteria:

          -  Being unable to consent for self

          -  Inability to take enteral medications

          -  Unwillingness to enroll in study

          -  Patient has a documented allergy to vancomycin

          -  Patient has a documented life expectancy shorter than treatment course (14 days)

          -  Patient is unwilling or unable to provide stool samples in the outpatient setting
             after discharge

          -  Diagnosis of C. difficile colitis [NAAT (+) and toxin EIA (+) within 3 months of
             enrollment).

          -  New onset of fever within 24 hours prior to the onset of diarrhea during index
             admission

          -  New onset of abdominal distention within 24 hours prior to the onset of diarrhea
             during index admission

          -  Presence of toxic megacolon

          -  Presence of clinical sepsis. Sepsis will be defined as a Sequential [Sepsis-related]
             Organ Failure Assessment (SOFA) score of 2 points or more as per 2016 definitions

          -  Absolute neutrophil count &lt;500
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Munoz-Price, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Munoz-Price, M.D., Ph.D.</last_name>
    <phone>(414) 955-8020</phone>
    <email>smunozprice@mcw.edu</email>
  </overall_contact>
  <reference>
    <citation>Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Jun 11;372(24):2369-70. doi: 10.1056/NEJMc1505190.</citation>
    <PMID>26061850</PMID>
  </reference>
  <reference>
    <citation>Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):206-16. doi: 10.1038/nrgastro.2016.25. Epub 2016 Mar 9. Review.</citation>
    <PMID>26956066</PMID>
  </reference>
  <reference>
    <citation>Theriot CM, Koenigsknecht MJ, Carlson PE Jr, Hatton GE, Nelson AM, Li B, Huffnagle GB, Z Li J, Young VB. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114. doi: 10.1038/ncomms4114.</citation>
    <PMID>24445449</PMID>
  </reference>
  <reference>
    <citation>Theriot CM, Bowman AA, Young VB. Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. mSphere. 2016 Jan 6;1(1). pii: e00045-15. doi: 10.1128/mSphere.00045-15. eCollection 2016 Jan-Feb.</citation>
    <PMID>27239562</PMID>
  </reference>
  <reference>
    <citation>Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010 Jan;31(1):21-7. doi: 10.1086/649016.</citation>
    <PMID>19929371</PMID>
  </reference>
  <results_reference>
    <citation>Aldrete SD, Kraft CS, Magee MJ, Chan A, Hutcherson D, Langston AA, Greenwell BI, Burd EM, Friedman-Moraco R. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period. Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12649.</citation>
    <PMID>27943501</PMID>
  </results_reference>
  <results_reference>
    <citation>Isaac S, Scher JU, Djukovic A, Jim√©nez N, Littman DR, Abramson SB, Pamer EG, Ubeda C. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother. 2017 Jan;72(1):128-136. Epub 2016 Oct 5.</citation>
    <PMID>27707993</PMID>
  </results_reference>
  <results_reference>
    <citation>Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, Nguyen HH, Huang B, Tang YW, Lee LW, Kim K, Taylor S, Romano PS, Panacek EA, Goodell PB, Solnick JV, Cohen SH. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med. 2015 Nov;175(11):1792-801. doi: 10.1001/jamainternmed.2015.4114.</citation>
    <PMID>26348734</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Participant data to be shared would consist of age categories, genders, treatment groups, Clostridium difficile status, microbiome profile and metabolic profile. The data will be anonymized to prevent the identification of individual patients from the data provided. The data would be made available through contacting the principal investigator directly.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

